Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19795045 | 0.90 | GRM4 (0.73) | GRM4CYP1A2 | |
| SCHEMBL19795056 | 0.87 | GRM4 (0.71) | GRM4CYP1A2 | |
| SCHEMBL19801649 | 0.87 | GRM4 (1.00) | GRM4CYP1A2 | |
| SCHEMBL19801931 | 0.86 | GRM4 (0.88) | GRM4CYP1A2 | |
| SCHEMBL19795201 | 0.85 | GRM4 (0.78) | GRM4CYP1A2 | |
| SCHEMBL19795245 | 0.85 | GRM4 (0.73) | GRM4CYP1A2 | |
| SCHEMBL19801934 | 0.85 | GRM4 (0.85) | GRM4CYP1A2 | |
| SCHEMBL19801651 | 0.85 | GRM4 (1.00) | GRM4CYP1A2 | |
| SCHEMBL19801905 | 0.84 | GRM4 (0.80) | GRM4CYP1A2 | |
| SCHEMBL19795064 | 0.84 | GRM4 (1.00) | GRM4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022746-A1 | INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-20180022746-A1 | INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022746-A1 | INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIK4, GRM4, GRIA4 | GRM4 2/4885CYP1A2 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.